← Leaderboards
Sandra J. Horning
Stanford University
$4,271,994
Attributed
$4,271,994
Total exposure
10
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $403.7K · FY2005–11$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
Funding mix
By agency
NIH$4,271,994 · 10
By mechanism
P01$2,049,676 · 2
R01$2,019,461 · 1
M01$202,857 · 7
Top collaborators
No co-investigators on record.
Most similar at Stanford University
Same institution · by research overlap
- Samuel Strober$36,157,957
- Robert S Negrin$29,816,136
- Asha Bhaskaran Pillai$2,775,962
- Edgar G. Engleman$35,389,843
- Ronald Levy$27,846,042
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectHuman Therapy EvaluationClinical ResearchNeoplasm /Cancer ChemotherapyLymphomaHodgkin'S DiseaseCytokineNeoplasm /Cancer Relapse /RecurrenceNonhodgkin'S LymphomaTositumomabCombination Cancer TherapyToxic EffectRecurrenceRituximabAutologous TransplantationDisease-Free SurvivalDosageTumorPatient Oriented ResearchNeoplasm /Cancer ImmunotherapyNeoplasm /Cancer Classification /StagingNeoplasm /Cancer Radiation TherapyBone Marrow TransplantationDrug Administration Rate /Duration
Grant awards (29)
Autografting for Lymphoma$351,664
P01 · FY2011 · CA · contact PI
Autografting for Lymphoma$387,482
P01 · FY2010 · CA · contact PI
Autografting for Lymphoma$382,673
P01 · FY2009 · CA · contact PI
Autografting for Lymphoma$373,636
P01 · FY2008 · CA · contact PI
CLINICAL TRIAL: EVALUATE THE EFFICACY OF ANTI-CD20 ANTIBODY IN LYMPHOCYTE PREDOM$3,641
M01 · FY2008 · RR · contact PI
Autografting for Lymphoma$332,773
P01 · FY2007 · CA · contact PI
EFFICACY OF ANTI-CD20 ANTIBODY IN LYMPHOCYTE PREDOMINANT HODGKIN'S DISEASE$21,065
M01 · FY2007 · RR · contact PI
EFFICACY OF ANTI-CD20 ANTIBODY IN LYMPHOCYTE PREDOMINANT HODGKIN'S DISEASE$18,681
M01 · FY2006 · RR · contact PI
Clinical Investigation in Hodgkin's Disease$388,964
R01 · FY2005 · CA
EFFICACY OF ANTI-CD20 ANTIBODY IN LYMPHOCYTE PREDOMINANT HODGKIN'S DISEASE$13,364
M01 · FY2005 · RR
TREATMENT OF PATIENTS WITH LARGE B-CELL LYMPHOMA$1,336
M01 · FY2005 · RR
Clinical Investigation in Hodgkin's Disease$379,767
R01 · FY2004 · CA
Evaluate the Efficacy of Anti-CD20 Antibody in Hodgkin's$7,112
M01 · FY2004 · RR
A Phase II Study: Rituximab, rhuMAb VEGF (bevacizumab)$1,778
M01 · FY2004 · RR
Clinical Investigation in Hodgkin's Disease$370,547
R01 · FY2003 · CA
Clinical Investigation in Hodgkin's Disease$359,781
R01 · FY2002 · CA
AUTOGRAFTING FOR LYMPHOMA$0
P01 · FY2002 · CA
Clinical &laboratory studies of post-translation lymphoproliferative disorder$0
P01 · FY2002 · CA
CLINICAL INVESTIGATIONS IN HODGKINS DISEASE$264,046
R01 · FY2001 · CA
PHASE II STUDY OF IODINE 131 ANTI BI ANTIBODY FOR NON HODGKINS LYMPHOMA$134,676
M01 · FY2001 · RR
AUTOGRAFTING FOR LYMPHOMA$0
P01 · FY2001 · CA
Clinical &laboratory studies of post-translation lymphoproliferative disorder$0
P01 · FY2001 · CA
PHASE II STUDY OF IODINE 131 ANTI BI ANTIBODY FOR NON HODGKINS LYMPHOMA$0
M01 · FY2001 · RR
CLINICAL INVESTIGATIONS IN HODGKINS DISEASE$256,356
R01 · FY2000 · CA
AUTOGRAFTING FOR LYMPHOMA$221,448
P01 · FY2000 · CA
PHASE II STUDY OF IODINE 131 ANTI BI ANTIBODY FOR NON HODGKINS LYMPHOMA$602
M01 · FY2000 · RR
PHASE I/II TRIAL OF PSC 833 AND OTHERS IN NONHODGKINS LYMPHOMA$602
M01 · FY2000 · RR
Clinical &laboratory studies of post-translation lymphoproliferative disorder$0
P01 · FY2000 · CA
AUTOGRAFTING FOR LYMPHOMA$0
P01 · FY2000 · CA